At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 242 enrolled
Drug / intervention
flortaucipir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation
In Brief
A Phase 3 clinical trial evaluating flortaucipir F 18 for Alzheimer Disease. Completed, enrolled 242 participants across 1 site.
Detailed Summary
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionApr 2019
TodayJul 2026
First PostedApr 3, 2019
Enrollment StartMar 26, 2019
Primary CompletionApr 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.2 years ago
Interventions
flortaucipir F 18drug
No study drug will be administered.